MXPA03003980A - Uso de melagatran para la elaboracion de un medicamento para el tratamiento de transtornos isquemicos. - Google Patents

Uso de melagatran para la elaboracion de un medicamento para el tratamiento de transtornos isquemicos.

Info

Publication number
MXPA03003980A
MXPA03003980A MXPA03003980A MXPA03003980A MXPA03003980A MX PA03003980 A MXPA03003980 A MX PA03003980A MX PA03003980 A MXPA03003980 A MX PA03003980A MX PA03003980 A MXPA03003980 A MX PA03003980A MX PA03003980 A MXPA03003980 A MX PA03003980A
Authority
MX
Mexico
Prior art keywords
melagatran
medicament
manufacture
treatment
ischemic disorders
Prior art date
Application number
MXPA03003980A
Other languages
English (en)
Inventor
David Gustafsson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MXPA03003980A publication Critical patent/MXPA03003980A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MXPA03003980A 2000-11-06 2000-11-09 Uso de melagatran para la elaboracion de un medicamento para el tratamiento de transtornos isquemicos. MXPA03003980A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/705,912 US6462021B1 (en) 2000-11-06 2000-11-06 Use of low molecular weight thrombin inhibitor
PCT/SE2000/002204 WO2002036157A1 (en) 2000-11-06 2000-11-09 Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders

Publications (1)

Publication Number Publication Date
MXPA03003980A true MXPA03003980A (es) 2003-08-19

Family

ID=24835453

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03003980A MXPA03003980A (es) 2000-11-06 2000-11-09 Uso de melagatran para la elaboracion de un medicamento para el tratamiento de transtornos isquemicos.

Country Status (14)

Country Link
US (1) US6462021B1 (es)
EP (1) EP1333855A1 (es)
JP (2) JP2004512376A (es)
KR (1) KR20040004431A (es)
CN (1) CN1455679A (es)
AU (2) AU2562501A (es)
BR (1) BR0017367A (es)
CA (1) CA2428012A1 (es)
IL (1) IL155431A0 (es)
MX (1) MXPA03003980A (es)
NO (1) NO20032006L (es)
NZ (1) NZ525487A (es)
WO (1) WO2002036157A1 (es)
ZA (1) ZA200303013B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904377D0 (sv) * 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
SE0200198D0 (sv) 2002-01-23 2002-01-23 Astrazeneca Ab New use
SE0201374D0 (sv) * 2002-05-06 2002-05-06 Astrazeneca Ab Pharmaceutical combination
SE0201373D0 (sv) * 2002-05-06 2002-05-06 Astrazeneca Ab Combination therapy
US20050288253A1 (en) 2002-09-09 2005-12-29 Trigen Limited Boronic acid salts
MXPA05002662A (es) 2002-09-09 2005-09-20 Trigen Ltd Sales de metal multivalente de acidos boronicos para el tratamiento de trombosis.
GB0306615D0 (en) * 2003-03-22 2003-04-30 Astrazeneca Ab New use
BRPI0715492A2 (pt) * 2006-07-17 2013-03-19 Boehringer Ingelheim Int uso de inibidores diretos de trombina

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
SE504185C2 (sv) 1994-11-08 1996-12-02 Astra Ab Lagringsstabil vattenlösning för infusion av trombininhibitorer
SE9404196D0 (sv) 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
ES2186807T3 (es) 1995-10-24 2003-05-16 Merck & Co Inc Inhibidores de trombina.
AR005245A1 (es) * 1995-12-21 1999-04-28 Astrazeneca Ab Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion
SE9601556D0 (sv) 1996-04-24 1996-04-24 Astra Ab New pharmaceutical formulation of a thrombin inhibitor for parenteral use
SE9602145D0 (sv) 1996-05-31 1996-05-31 Astra Ab New improved formulation for treatment of thromboembolism
SE9603724D0 (sv) 1996-10-11 1996-10-11 Astra Ab New pharmaceutical parenteral formulation of a thrombin inhibitor
SE9704401D0 (sv) 1997-11-28 1997-11-28 Astra Ab Matrix pellets for greasy, oily or sticky drug substances
SE9704400D0 (sv) 1997-11-28 1997-11-28 Astra Ab Porous inorganic particles as carriers for drug substances
SE9802938D0 (sv) 1998-09-01 1998-09-01 Astra Ab Improved stability for injection solutions
SE9802973D0 (sv) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
SE9900070D0 (sv) 1999-01-13 1999-01-13 Astra Ab New use
AR023510A1 (es) * 1999-04-21 2002-09-04 Astrazeneca Ab Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina.

Also Published As

Publication number Publication date
NO20032006D0 (no) 2003-05-05
ZA200303013B (en) 2004-07-16
IL155431A0 (en) 2003-11-23
NO20032006L (no) 2003-07-01
EP1333855A1 (en) 2003-08-13
BR0017367A (pt) 2003-10-07
US6462021B1 (en) 2002-10-08
KR20040004431A (ko) 2004-01-13
AU2001225625B2 (en) 2006-06-15
CA2428012A1 (en) 2002-05-10
JP2005120098A (ja) 2005-05-12
AU2562501A (en) 2002-05-15
NZ525487A (en) 2004-11-26
JP2004512376A (ja) 2004-04-22
CN1455679A (zh) 2003-11-12
WO2002036157A1 (en) 2002-05-10

Similar Documents

Publication Publication Date Title
DE60223254D1 (de) Verzögert freisetzende formulierungen von oxymorphon
YU37602A (sh) Derivat pirolidinacetamida sam ili u kombinaciji za tretman poremećaja cns
AU2002321105A1 (en) Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
WO2006067165A3 (en) Indolidone derivatives for the treatment or prevention of fibrotic diseases
GB0225475D0 (en) Therapeutic agents
WO2003009838A1 (fr) Utilisation de composes de stilbene dans la preparation de medicaments pour le traitement ou la prevention du diabete et des maladies associees au retrovirus
CY1107465T1 (el) Μελαγατρανη για τη θepαπευτικη αντιμετωπιση φλεγμονων
ATE402176T1 (de) Pyrrolidin- und azetidinverbindungen alsccr5- antagonisten
HK1051497A1 (en) Agents, such as nicotinamide or cadpr for the treatment of skin disorders
MXPA03010761A (es) Combinaciones farmaceuticas.
GB0002336D0 (en) Medicaments
MXPA03003980A (es) Uso de melagatran para la elaboracion de un medicamento para el tratamiento de transtornos isquemicos.
ATE360428T1 (de) Analgetisches arzneimittel
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
PT1206444E (pt) Compostos que inibem a actividade da triptase
HK1057332A1 (en) Use of 3-benzoylphenylacetic acid derivatives for the treatment of retinal disorders
AU2173101A (en) Use of carboxy compounds such as 2(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride as anti-inflammatory agents
MXPA02006146A (es) Uso de metabolitos bioactivos de gepirona para el tratamiento de desordenes psicologicos.
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.
GR20010100390A (el) Χρηση του diclofenac h αποδεκτων αλατων αυτου για την αντιμετωπιση των εγκαυματων.
NO20042586L (no) Behandlingsfremgangsmate
MXPA03010350A (es) Uso de un gatran para la elaboracion de un medicamento para el tratamiento de fibrosis pulmonar.
HUP0004475A2 (hu) Gyógyszerkészítmény
AU4453301A (en) Use of spirolaxin for the treatment of diseases associated with abnormal angiogenesis

Legal Events

Date Code Title Description
FG Grant or registration